pSer129 pathology |
|---|
| | SNpc | Amyg. | Cing. |
|---|
LBD |
Case 1 | ++ | +++ | +++ |
Case 2 | +++ | +++ | +++ |
Case 3 | ++ | +++ | +++ |
Case 4 | +++ | ++ | + |
Case 5 | ++ | ++ | ++ |
Case 6 | ++ | + | ++ |
Case 7 | +++ | +++ | +++ |
Case 8 | +++ | +++ | +++ |
Case 9 | ++ | ++ | ++ |
AD/ALB |
Case 15 | – | −/+ | – |
Case 16 | – | + | – |
Case 17 | −/+ | ++ | – |
Case 18 | – | +++ | – |
Case 19 | – | ++ | – |
Case 20 | – | ++ | – |
Case 21 | – | ++ | – |
Case 22 | – | + | – |
Case 23 | – | +++ | – |
- Following immunohistochemical staining with antibody EP1536Y and no formic acid retrieval, semi-quantitative grading was assigned to each LBD and AD/ALB case for 3 separate regions (SNpc substantia nigra pars compacta, cing. cingulate cortex, amyg. amygdala). The presence of pSer129 positive inclusions was semi-quantitatively graded at 10x magnification on a multi-tiered scale, with “-” representing non-reactivity, “−/+” very rare, “+” mild, “++” moderate, and “+++” representing the strongest level of reactivity
